{"id":"W2784258094","doi":"10.1002/cncr.31234","title":"Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Dasatinib; GiST; Clinical endpoint; Imatinib mesylate; Internal medicine; Clinical trial; Imatinib; Positron emission tomography; Progressive disease; Tyrosine-kinase inhibitor; Phases of clinical research; Cancer; Surgery; Gastroenterology; Chemotherapy; Nuclear medicine; Stromal cell","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003238422,0.001821948,0.002211416,0.0005319706,0.0004235219,0.00110534,0.0006285521,0.001393935,0.002255179],"category_scores_gemma":[0.001139958,0.0004399937,0.001594758,0.0003773414,0.0008536616,0.0007710206,0.0005073342,0.002069401,0.0005486609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009396583,"about_ca_system_score_gemma":0.001624143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005884559,"about_ca_topic_score_gemma":0.001543304,"domain_scores_codex":[0.9991585,0.0005114268,0.00003415961,0.0001120968,0.00005427721,0.0001294619],"domain_scores_gemma":[0.9991466,0.0001160725,0.0002059441,0.00007532514,0.00005783531,0.000398162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8843464,0.02853845,0.008508927,0.0006234761,0.001359644,0.0002998094,0.0002098611,0.0023901,0.01903627,0.0001546432,0.004552151,0.0499801],"study_design_scores_gemma":[0.7567426,0.2261932,0.01249929,0.00003292506,0.0004813658,0.0002954231,0.00003570755,0.0009735803,0.001524998,0.0001298777,0.001062659,0.00002840191],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943017,0.002132506,0.0002429266,0.0005160883,0.0001086411,0.001008523,0.001009058,0.00004904578,0.0006313695],"genre_scores_gemma":[0.9869171,0.00187029,0.001186328,0.001030592,0.0003284983,0.002785392,0.004085844,0.00003247927,0.00176352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003238422,"threshold_uncertainty_score":0.01712662,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3396339336548623,"score_gpt":0.5669099352753292,"score_spread":0.2272760016204668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}